Nothing Special   »   [go: up one dir, main page]

Lui, 2024 - Google Patents

T Cell Antigen Receptor Signaling Defects in Immune Deficiencies

Lui, 2024

Document ID
5472384810189175960
Author
Lui V
Publication year

External Links

Snippet

The work presented in the first section of this thesis describes how a novel homozygous P440S mutation in LCK results in decreased LCK protein expression and defective TCR signaling. The severe signaling defect impedes thymocyte development, which results in T …
Continue reading at search.proquest.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Johnson et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Serr et al. Type 1 diabetes vaccine candidates promote human Foxp3+ Treg induction in humanized mice
Serwas et al. Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis
Keller et al. Early onset combined immunodeficiency and autoimmunity in patients with loss-of-function mutation in LAT
Picarda et al. Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells
Vavassori et al. Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper‐IgM syndrome
Salojin et al. Genetic deletion of Mst1 alters T cell function and protects against autoimmunity
US20220152176A1 (en) Cancer biomarkers for durable clinical benefit
Woolaver et al. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts
Janssen et al. DOCK8 enforces immunological tolerance by promoting IL-2 signaling and immune synapse formation in Tregs
Fernandes et al. Discovery of surrogate agonists for visceral fat Treg cells that modulate metabolic indices in vivo
Hiwa et al. NR4A family members regulate T cell tolerance to preserve immune homeostasis and suppress autoimmunity
Ali et al. T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
Catak et al. Comparing the levels of CTLA‐4‐dependent biological defects in patients with LRBA deficiency and CTLA‐4 insufficiency
Nguyen et al. Cbl-b deficiency prevents functional but not phenotypic T cell anergy
Afzali et al. B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4
Lui et al. A partial human LCK defect causes a T cell immunodeficiency with intestinal inflammation
US20170320951A1 (en) Methods for diagnosing and treating cd1d restricted gamma/delta t cell lymphomas
Lui T Cell Antigen Receptor Signaling Defects in Immune Deficiencies
Raveney et al. Neuropilin‐1 (NRP1) expression distinguishes self‐reactive helper T cells in systemic autoimmune disease
Hrdinka et al. Normal development and function of T cells in proline rich 7 (Prr7) deficient mice
US20230258626A1 (en) Follicular helper t cell profile for identifying patients with type 1 diabetes suitable for treatment with ctla-4-ig
Yazdanpanah et al. Autoimmune disorders associated with common variable immunodeficiency: prediction, diagnosis, and treatment
Rezk Interactions between B cells and CD8+ T cells in multiple sclerosis
Mammadli et al. Inhibition of ITK differentiates GVT and GVHD in allo-HSCT